Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
主要な著者: | Taylor, P, Takeuchi, T, Burmester, G, Durez, P, Smolen, J, Deberdt, W, Zhong, J, Teres, JR, Bello, N, Winthrop, K, Pope, J |
---|---|
フォーマット: | Conference item |
言語: | English |
出版事項: |
Journal of Rheumatology
2022
|
類似資料
-
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
著者:: Taylor, P, 等
出版事項: (2021) -
Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
著者:: Weinblatt, M, 等
出版事項: (2017) -
Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
著者:: Weinblatt, M, 等
出版事項: (2018) -
Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
著者:: Taylor, P, 等
出版事項: (2019) -
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
著者:: Gerd Burmester, 等
出版事項: (2020-02-01)